38%) og højere hos patienter med kemoterapifølsomt relaps sammenlignet med kemoterapi- resistent relaps (defineret som en responsvarighed < 3 måneder) (50% vs.
38%), and higher in patients with chemosensitive relapse as compared to chemoresistant (defined as duration of response < 3 months) relapse (50% vs.